While Sovaldi will be available for patients at $300 a bottle, about one-tenth the price in the United States, later this year, the generic version, still in trials, is expected to be available soon after.
Gilead Sciences Inc said it would allow generic-drug makers to produce a new version of its Sovaldi hepatitis C treatment. The new drug is currently still undergoing clinical trials, but Gilead believes the new version will be more effective at treating the hepatitis C virus, which infects 130 million people worldwide a year.
“This compound will offer over 90% cure rate for all genotypes, with one pill a day for 12 weeks,” said Gregg Alton, Gilead’s head of corporate and medical affairs. Earlier this month, India’s patent office rejected one of the company’s patents on Sovaldi, saying it failed to meet the threshold for improvement over a previous compound developed by another company. Without the patent protection the drug could be reproduced by generic companies even without its approval.
Link to the complete article on The Wall Street Journal: http://on.wsj.com/1xYxXj2
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More